{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 39,
  "pageCount": 41,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/39",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.91,
        "x": 0.07,
        "y": 0.61
      },
      "kind": "list",
      "text": "COVID vaccine candidate VLA2001: Phase 1/2 initial data reported, Phase 3 data expected in Q3 2021; Regulatory submission planned autumn 2021 assuming clinical data positive; Further supply deals subject to negotiations and capacity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05a36539-8ad5-478d-996e-94e6d43e6426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.91,
        "x": 0.07,
        "y": 0.43
      },
      "kind": "list",
      "text": "Chikungunya vaccine candidate VLA1553: Initial Phase 3 data expected mid-2021; Phase 3 now fully recruited",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c11b13f3-384b-4cf1-984b-3782c4f8e19d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.91,
        "x": 0.07,
        "y": 0.27
      },
      "kind": "list",
      "text": "Lyme disease vaccine candidate VLA15: Further Phase 2 milestones and read-outs during 2021; Phase 2 study VLA15-221, including pediatric development, initiated March 2021;",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaa2e2f0-ffe0-4208-a819-8d9b7cea390f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.53,
        "x": 0.067,
        "y": 0.067
      },
      "kind": "title",
      "text": "Key Upcoming Catalysts and Potential Inflection Points",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d140475-b75d-4a18-bd97-b8c32f2b7424",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 39,
      "from": 37,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "baebb8a3-07c5-41ef-adea-6528555361e3",
      "evidence": "Slides 37-39: Use of funds and upcoming catalysts",
      "position": 1,
      "objective": "Why is now the right time to invest in Valneva?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}